Comparison · NCT00364351-d9f6328e
Vandetanib vs Erlotinib: Disease Control Rate (DCR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Erlotinib: Disease Control Rate (DCR). Trial comparisons, record NCT00364351-d9f6328e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00364351-d9f6328e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.408 | 0.37 | 0.447 | wilson | |
| Risk in group 2 | 0.392 | 0.354 | 0.431 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0155 | -0.039 | 0.0698 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.907 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.07 | 0.85 | 1.34 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib than on Erlotinib | 64.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | Vandetanib 300 mg | 254 | 623 | OG000 |
| Group 2 | Erlotinib | Erlotinib | 242 | 617 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Disease Control Rate (DCR)
- Description
Disease control rate is defined as the number of patients who achieved disease control at least 8 weeks following randomisation. Disease control is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \>= 8 weeks as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere, PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions and SD \>= 8 is assigned to patients who have not responded and have no evidence of progression at least 8 weeks after randomisation.
- Time frame
- RECIST tumour assessments carried out every 4 weeks until week 16 then every 8 weeks thereafter (+/- 3 days) from randomisation until objective progression
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
- NCT number
- NCT00364351
- Phases
- PHASE3
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Vandetanib, Erlotinib
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00364351?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00364351-d9f6328e